BLPH insider trading

Bellerophon Therapeutics, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades
171
Last 90 days
0
Buys / sells
38% / 6%
Market cap
—

BLPH insider activity at a glance

FilingIQ tracks 171 insider transactions for BLPH in filings since Feb 23, 2015. The most recent transaction is dated Oct 13, 2023.

Across the full history, 65 open-market purchases and 11 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.

Latest BLPH Form 4 filings

Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.

Frequently asked

How many insider trades does FilingIQ track for BLPH?
FilingIQ tracks 171 Form 4 insider transactions for BLPH (Bellerophon Therapeutics, Inc.), covering filings from Feb 23, 2015 onwards. 0 of those are dated within the last 90 days.
Are BLPH insiders net buyers or net sellers?
Across the full Form 4 history for BLPH, 65 transactions (38%) were open-market purchases and 11 (6%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BLPH insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.

Methodology & sources

Every BLPH insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.